ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company's wholly owned subsidiary, Aleor Dermaceuticals Limited has received US Food and Drug Administration (USFDA) Final Approval for Clobetasol Propionate Foam, 0.05%. Please find enclosed herewith our press release. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
The exchange is hereby informed that the Company will hold Post Results Conference Call on 2nd May, 2022 as per the enclosed details. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Board to consider FY22 Results & Dividend on May 02, 2022
Alembic Pharmaceuticals Ltd has informed BSE that a Meeting of Board of Directors of the Company will be held on May 02, 2022, inter alia, to transact the following business:1. To consider and approve Audited Financial Results of the Company for the quarter and financial year ended March 31, 2022.2. To consider and recommend dividend on equity shares, if any, for the financial year ended March 31, 2022.Pursuant to the Company''s Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives, the trading window for dealing in securities of the Company which was closed from April 01, 2022, will reopen 48 hours after the declaration of the financial results. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Board Meeting Intimation for To Consider And Approve Audited Financial Results Of The Company For The Quarter And Financial Year Ended 31St March, 2022.
ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/05/2022 ,inter alia, to consider and approve With reference to the captioned matter, the exchange is hereby informed that a Meeting of Board of Directors of the Company will be held on Monday, 2nd May, 2022, inter-alia to transact the following business: 1. To consider and approve Audited Financial Results of the Company for the quarter and financial year ended 31st March, 2022. 2. To consider and recommend dividend on equity shares, if any, for the financial year ended 31st March, 2022. Pursuant to the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives, the trading window for dealing in securities of the Company which was closed from 1st April, 2022, will re-open 48 hours after the declaration of the financial results. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record.
Alembic Pharma arm gets final USFDA nod for generic version of Lidocaine and Prilocaine cream
The final approval granted by the US Food Drug Administration (USFDA) is for its abbreviated new drug application (ANDA) for Lidocaine and Prilocaine cream of strength 2.5 per cent/2.5 per cent, Alembic said in a statement. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company's wholly owned subsidiary, Aleor Dermaceuticals Limited has received US Food and Drug Administration (USFDA) Final Approval for Lidocaine and Prilocaine Cream USP, 2.5%/2.5%. Please find enclosed herewith our press release. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliance Certificate For The Financial Year Ended 31St March, 2022
With reference to the captioned subject, we hereby confirm that all activities in relation to both physical and electronic share transfer facility are maintained by the Company's Registrar and Share Transfer Agent viz. Link Intime India Private Limited, which is a SEBI approved Category-I Registrar & Transfer Agent, registered with the Securities and Exchange Board of India (SEBI Registration Number: INR000004058). We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Certificate Under Regulation 40(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Financial Year Ended 31St March, 2022
With reference to the captioned subject, we enclose herewith Certificate under Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the financial year ended 31st March, 2022, issued by M/s. Samdani Shah & Kabra, Practising Company Secretaries, Vadodara. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
With reference to the captioned subject, please find attached herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March, 2022, received from M/s. Link Intime India Private Limited, Registrar and Share Transfer Agent of our Company. We request you to kindly take the same on record.